366017-09-6

Basic information

• Product Name: Mubritinib
• Synonyms: MUBRITINIB;1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole;TAK 165;Mubritinib(TAK 165);(E)-1-(4-(4-((2-(4-(trifluoromethyl)styryl)oxazol-4-yl)methoxy)phenyl)butyl)-1H-1,2,3-triazole;1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole Mubritinib (TAK 165);Mubritinib 1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole;(E)-4-((4-(4-(1H-1,2,3-Triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole
• CAS NO: 366017-09-6
• Molecular Formula: C25H23F3N4O2
• Molecular Weight: 468.47
• Product Categories: Inhibitors
• Mol File: 366017-09-6.mol
• Article Data: 0

Chemical Properties

• Melting Point: 158.0 to 162.0 °C
• Boiling Point: 620.897 °C at 760 mmHg
• Flash Point: 329.307 °C
• Appearance: /
• Density: 1.258 g/cm³
• Vapor Pressure: 2.43E-15mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: Store at +4°C
• PKA: 1.45±0.10(Predicted)
• CAS DataBase Reference: Mubritinib(CAS DataBase Reference)
• NIST Chemistry Reference: Mubritinib(366017-09-6)
• EPA Substance Registry System: Mubritinib(366017-09-6)

Safety Data

• Hazardous Substances Data: 366017-09-6(Hazardous Substances Data)

Usage

Description

Mubritinib is a small molecule inhibitor that selectively targets CTNNB1-, KRAS-, and MYC-driven human cancer cell growth. It is designed to work in combination with existing drugs to enhance their effectiveness against various types of cancer.

Uses

Used in Anticancer Applications:
Mubritinib is used as a targeted therapy for the selective inhibition of cancer cell growth driven by CTNNB1, KRAS, or MYC. It is particularly effective when combined with existing drugs, as it enhances the overall treatment efficacy and selectively targets cancer cells while minimizing damage to healthy cells.
Used in Drug Combination Therapy:
Mubritinib is used as a component in drug combination therapy to improve the effectiveness of existing treatments for various types of cancer. By combining Mubritinib with other drugs, it can help overcome resistance and increase the sensitivity of cancer cells to the treatment, leading to better outcomes for patients.

Biological Activity

Potent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC 50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC 50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo .

InChI:InChI=1/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+